Five-Year Incidence of Progression to Ankle Osteoarthritis in Patients with and without Glucagon-like Peptide-1 Receptor Agonist Therapy
Published online on March 10, 2026
Abstract
Foot & Ankle Specialist, Ahead of Print.
BackgroundGlucagon-like peptide-1 receptor agonists (GLP) are widely prescribed for type 2 diabetes mellitus (T2DM) and obesity, with established metabolic and anti-inflammatory benefits. Their musculoskeletal impact, particularly on joint-specific ...
BackgroundGlucagon-like peptide-1 receptor agonists (GLP) are widely prescribed for type 2 diabetes mellitus (T2DM) and obesity, with established metabolic and anti-inflammatory benefits. Their musculoskeletal impact, particularly on joint-specific ...